title: Metabolomics in noninvasive breast cancer.
abstract: Breast cancer remains the most leading cause of death among women worldwide. Common methods for diagnosis and surveillance include mammography, histopathology and blood tests. The major drawback of mammography is the high rate of false reports, aside from the risk from repeated exposure to harmful ionizing radiations; histopathology is time consuming and often prone to subjective interpretations; blood-based tests are attractive, but lack the sensitivity and specificity. Obviously, more sensitive biomarkers for early detection and molecular targets for better treating breast cancer are urgently needed. Fortunately, molecular level 'omics' diagnosis is becoming increasingly popular; metabolomics, diagnosis based on 'metabolic fingerprinting' may provide clinically useful biomarkers applied toward identifying metabolic alterations and has introduced new insights into the pathology of breast cancer. By applying advanced analytical and statistical tools, metabolomics involves the comprehensive profiling of the full complement of low molecular weight compounds in a biological system and could classify the basis of tumor biology of breast cancer, to identify new prognostic and predictive markers and discover new targets for future therapeutic interventions. This advanced bioanalytic methods may now open new avenues for diagnostics in cancer via discovery of biomarkers. In this review we take a closer look at the metabolomics used within the field of breast cancer diagnosis. Further, we highlight the most interesting metabolomics publications and discuss these in detail; additional studies are mentioned as a reference for the interested reader. A general trend is an increased focus on biological interpretation rather than merely the ability to classify samples.
authors.affiliation: National TCM Key Lab of Serum Pharmacochemistry, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin 150040, China; Key Pharmacometabolomics Platform of Chinese Medicines, Heping Road 24, Harbin 150040, China. Electronic address: aihuatcm@yeah.net.
authors.forename: Ai-hua
authors.initials: AH
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Shi
authors.initials: S
authors.lastname: Qiu
authors.forename: Xi-jun
authors.initials: XJ
authors.lastname: Wang
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D016022:Case-Control Studies; D003568:Cytidine Monophosphate / Q000378:metabolism*; D042241:Early Diagnosis; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D005994:Glycerophosphates / Q000378:metabolism*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D055432:Metabolomics; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D005227:Fatty Acids; D005994:Glycerophosphates; C029620:alpha-glycerophosphoric acid; C117025:pentadecanoic acid; D003568:Cytidine Monophosphate
keywords: Biomarkers; Breast cancer; Early diagnosis; Metabolites; Metabolomics